Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.23
-0.3%
$7.27
$2.81
$485.37
$2.45M5.75602,654 shs404,981 shs
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
$2.51
+2.4%
$4.92
$2.21
$1,844.85
$1.95M2.02165,387 shs369,005 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$3.46
-8.7%
$2.84
$1.72
$15.70
$4.58M0.171.00 million shs402,973 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$2.87
+0.3%
$3.23
$1.75
$9.37
$4.70M1.38807,882 shs12,412 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-0.31%-37.04%-34.35%-85.58%-99.98%
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
+2.45%+5.91%-32.35%-81.20%-99.84%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-8.71%+37.85%+24.46%+67.96%-34.22%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+0.35%+0.70%-9.75%+19.09%+1,492.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.2359 of 5 stars
3.55.00.00.02.90.01.3
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
0.2382 of 5 stars
0.02.00.00.03.30.00.0
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.7167 of 5 stars
0.04.00.00.02.50.00.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.3906 of 5 stars
0.03.00.00.03.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.00
Buy$219,040.006,781,324.15% Upside
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
4.00
Strong BuyN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.11M0.79N/AN/A$65.21 per share0.05
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/AN/AN/AN/A($73.54) per shareN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.60M0.91N/AN/A$20.64 per share0.17
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.33N/AN/A$2.73 per share1.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
-$17.80M-$534.48N/AN/AN/AN/A-435.57%N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$7.68M-$12.09N/AN/A-168.87%-107.93%-82.97%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.10N/AN/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)

Latest APVO, CDT, SNOA, and INM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
5/15/2025Q1 2025
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$84.20-$87.80-$3.60-$4.39N/AN/A
5/15/2025Q1 2025
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/A-$19.80N/A-$1.32N/AN/A
5/12/2025Q3 2025
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A-$1.94N/A-$1.94N/A$1.26 million
3/28/2025Q4 2024
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/A-$304.95N/A-$20.33N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
0.67
0.67
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/A
1.31
1.31
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.06
3.49
3.04
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38

Institutional Ownership

CompanyInstitutional Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
8.06%
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
3.29%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
50760,000756,000Not Optionable
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
3800,000766,000Not Optionable
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
101.21 million1.19 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.58 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$3.23 -0.01 (-0.31%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$3.19 -0.04 (-1.11%)
As of 06/26/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Conduit Pharmaceuticals stock logo

Conduit Pharmaceuticals NASDAQ:CDT

$2.51 +0.06 (+2.45%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$2.62 +0.12 (+4.58%)
As of 06/26/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$3.46 -0.33 (-8.71%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$3.48 +0.02 (+0.43%)
As of 06/26/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$2.87 +0.01 (+0.35%)
Closing price 06/26/2025 03:59 PM Eastern
Extended Trading
$2.88 +0.01 (+0.35%)
As of 06/26/2025 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.